Skip to content

Study · Animal study (in vivo) · mouse · 2019

15 results

Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice.

Cheng XL, Ding F, Wang DP, Zhou L, Cao JM

Peptides3 Aug 2019Cited by 9 (Europe PMC)

PMID31386895 (opens in a new tab)DOI10.1016/j.peptides.2019.170122 (opens in a new tab)PepBankPUB-31386895
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin decreased serum total cholesterol versus saline.

    In plain wordsIn mice with artery disease, hexarelin lowered blood total cholesterol compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreaseSerum total cholesterol
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin decreased serum triglycerides versus saline.

    In plain wordsIn mice with artery disease, hexarelin lowered blood triglycerides compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreaseSerum triglycerides
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin decreased serum LDL-c versus saline.

    In plain wordsIn mice with artery disease, hexarelin lowered blood LDL cholesterol compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreaseSerum LDL-c
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin increased serum HDL-c versus saline.

    In plain wordsIn mice with artery disease, hexarelin raised blood HDL cholesterol compared with saline.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum HDL-c
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin attenuated the formation of atherosclerotic plaques versus saline.

    In plain wordsIn mice with artery disease, hexarelin reduced artery plaque formation compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreaseAtherosclerotic plaque formation
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-/- mice with atherosclerosis, hexarelin attenuated neointima formation versus saline.

    In plain wordsIn mice with artery disease, hexarelin reduced thickening of the inner artery layer compared with saline.

    Peptide
    Hexarelin
    Outcome
    DecreaseNeointima formation
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased serum TC, TG and LDL-c, increased serum HDL-c and attenuated the formation of atherosclerotic plaques and neointima compared with the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In ApoE-/- mice with atherosclerosis, hexarelin decreased aortic CD68 expression that was elevated in the AS group.

    In plain wordsIn mice with artery disease, hexarelin lowered CD68, a macrophage marker, in the aorta.

    Peptide
    Hexarelin
    Outcome
    DecreaseAortic CD68 expression
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased the aortic expressions of CD68 and LOX-1 which were elevated in the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  8. 08AnimalAnimal study (in vivo)Mechanism

    In ApoE-/- mice with atherosclerosis, hexarelin decreased aortic LOX-1 expression that was elevated in the AS group.

    In plain wordsIn mice with artery disease, hexarelin lowered LOX-1, an oxidized cholesterol receptor, in the aorta.

    Peptide
    Hexarelin
    Outcome
    DecreaseAortic LOX-1 expression
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin decreased the aortic expressions of CD68 and LOX-1 which were elevated in the AS group.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  9. 09AnimalAnimal study (in vivo)Mechanism

    In ApoE-/- mice with atherosclerosis, hexarelin increased GHSR expression in the aorta.

    In plain wordsIn mice with artery disease, hexarelin raised levels of its own receptor, GHSR, in the aorta.

    Peptide
    Hexarelin
    Outcome
    IncreaseAortic GHSR expression
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  10. 10AnimalAnimal study (in vivo)Mechanism

    In ApoE-/- mice with atherosclerosis, hexarelin suppressed ox-LDL uptake in the aorta.

    In plain wordsIn mice with artery disease, hexarelin reduced uptake of oxidized LDL cholesterol in the aorta.

    Peptide
    Hexarelin
    Outcome
    DecreaseAortic ox-LDL uptake
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  11. 11AnimalAnimal study (in vivo)Mechanism

    In ApoE-/- mice with atherosclerosis, hexarelin inhibited NF-κB activation in the aorta.

    In plain wordsIn mice with artery disease, hexarelin reduced NF-κB, an inflammation switch, in the aorta.

    Peptide
    Hexarelin
    Outcome
    DecreaseAortic NF-κB activation
    Study

    mousen: not reported in source

    ApoE-/- mice on high-lipid diet
    Comparator
    Saline (AS group)
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    100 μg/kg · subcutaneous · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
    1 context sentence
    Summary · context
    Mice were treated either with hexarelin (100 μg/kg s.c., q.d. for 3 months) (AS + Hex group) or saline (AS group).
  12. 12LabIn vitro (cells)Mechanism

    In RAW264.7 macrophages, hexarelin increased GHSR expression.

    In plain wordsIn cells, hexarelin raised levels of its own receptor, GHSR, in macrophages.

    Peptide
    Hexarelin
    Outcome
    IncreaseGHSR expression in RAW264.7 macrophages
    Study

    mousen: not reported in source

    RAW264.7 macrophages
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
  13. 13LabIn vitro (cells)Mechanism

    In RAW264.7 macrophages, hexarelin suppressed ox-LDL uptake.

    In plain wordsIn cells, hexarelin reduced uptake of oxidized LDL cholesterol by macrophages.

    Peptide
    Hexarelin
    Outcome
    Decreaseox-LDL uptake in RAW264.7 macrophages
    Study

    mousen: not reported in source

    RAW264.7 macrophages
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
  14. 14LabIn vitro (cells)Mechanism

    In RAW264.7 macrophages, hexarelin suppressed LOX-1 expression.

    In plain wordsIn cells, hexarelin lowered LOX-1, an oxidized cholesterol receptor, in macrophages.

    Peptide
    Hexarelin
    Outcome
    DecreaseLOX-1 expression in RAW264.7 macrophages
    Study

    mousen: not reported in source

    RAW264.7 macrophages
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.
  15. 15LabIn vitro (cells)Mechanism

    In RAW264.7 macrophages, hexarelin inhibited NF-κB activation.

    In plain wordsIn cells, hexarelin reduced NF-κB, an inflammation switch, in macrophages.

    Peptide
    Hexarelin
    Outcome
    DecreaseNF-κB activation in RAW264.7 macrophages
    Study

    mousen: not reported in source

    RAW264.7 macrophages
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin increased GHSR expression, suppressed ox-LDL uptake and LOX-1 expression and inhibited nuclear factor-kappa B (NF-κB) activation both in the aorta of ApoE-/- mice and in RAW264.7 macrophages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.